Clinical Trial Update: A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of BMS-986218 alone or with nivolumab plus docetaxel in metastatic castration-resistant prostate cancer has been terminated. Results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• BMS-986218 (non-fucosylated anti-CTLA-4 antibody)
• OPDIVO (nivolumab)
• Taxotere (docetaxel)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 2 | Status: TERMINATED | Results posted: 2025-06-10